SYDNEY, Australia – GenesisCare today announced that co-founder and long-term Chairman, David Vaux, will be retiring.
With Mr Vaux as Chairman the company has become a global leader in cancer treatment and cardiology with over 750,000 patient attendances in the last 12 months.
The company has grown from a strong Australian base to expand into the UK and Spain and will soon be operating services in China.
“I would like to recognise the wonderful doctors and staff of GenesisCare who deliver world class care to patients every day,” Mr Vaux said.
“This is the real success of GenesisCare and the company culture that fosters innovation and a “can – do, patients first” attitude. It’s been terrific to be part of it all.”
He also thanked current and former Board members for their support and said the company was poised for another round of growth.
“Our staff alongside doctor and manager shareholders, should feel confident that we have the right and unique mix of corporate partners, in China Resources Group – one of China’s leading conglomerates based out of Hong Kong – and in KKR & Co, who have re-joined our share register recently,” Mr Vaux said.
He said it has been a privilege as Chairman to been involved with Dan Collins, co-founder and CEO, since the very beginnings of GenesisCare in 2004.
Mr. Vaux said a comprehensive strategy to substantially grow the company over the next five years had been endorsed by the Board and with Mr Collins’ leadership this extraordinary opportunity to more than double the size and value of the business will be passionately pursued.
Mr Vaux said the Board has made arrangements for the appointment of a new Chairman and that staff and doctors at GenesisCare would be delighted with the announcement, which is expected soon.